Advertisement

Melanoma classification and management in the era of molecular medicine

Published:October 27, 2022DOI:https://doi.org/10.1016/j.det.2022.07.017

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mort R.L.
        • Jackson I.J.
        • Patton E.E.
        The melanocyte lineage in development and disease.
        Development. 2015; 142: 620-632
        • Lin J.Y.
        • Fisher D.E.
        Melanocyte biology and skin pigmentation.
        Nature. 2007; 445: 843-850
        • Vergara I.A.
        • Mintoff C.P.
        • Sandhu S.
        • et al.
        Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling.
        Nat Commun. 2021; 12: 1434
      1. Melanoma of the Skin - Cancer Stat Facts. SEER.
        (Available at:) (Accessed March 8, 2021)
        • Sandru A.
        • Voinea S.
        • Panaitescu E.
        • et al.
        Survival rates of patients with metastatic malignant melanoma.
        J Med Life. 2014; 7: 572-576
        • Joyce K.M.
        Surgical Management of Melanoma.
        in: Ward W.H. Farma J.M. Cutaneous melanoma: etiology and therapy. Codon Publications, 2017 (Available at:) (Accessed February 28, 2022)
        • Essner R.
        • Lee J.H.
        • Wanek L.A.
        • et al.
        Contemporary surgical treatment of advanced-stage melanoma.
        Arch Surg. 2004; 139 (; discussion 966-967): 961-966
        • Erdei E.
        • Torres S.M.
        A new understanding in the epidemiology of melanoma.
        Expert Rev Anticancer Ther. 2010; 10: 1811-1823
        • Koh H.K.
        • Geller A.C.
        • Miller D.R.
        • et al.
        Prevention and early detection strategies for melanoma and skin cancer. Current status.
        Arch Dermatol. 1996; 132: 436-443
        • Brem R.
        • Guven M.
        • Karran P.
        Oxidatively-generated damage to DNA and proteins mediated by photosensitized UVA.
        Free Radic Biol Med. 2017; 107: 101-109
        • Bruls W.A.
        • Slaper H.
        • van der Leun J.C.
        • et al.
        Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths.
        Photochem Photobiol. 1984; 40: 485-494
        • Leonardi G.C.
        • Falzone L.
        • Salemi R.
        • et al.
        Cutaneous melanoma: From pathogenesis to therapy (Review).
        Int J Oncol. 2018; 52: 1071-1080
        • Dawes S.M.
        • Tsai S.
        • Gittleman H.
        • et al.
        Racial disparities in melanoma survival.
        J Am Acad Dermatol. 2016; 75: 983-991
        • Brady J.
        • Kashlan R.
        • Ruterbusch J.
        • et al.
        Racial Disparities in Patients with Melanoma: A Multivariate Survival Analysis.
        Clin Cosmet Investig Dermatol. 2021; 14: 547-550
        • Zell J.A.
        • Cinar P.
        • Mobasher M.
        • et al.
        Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.
        J Clin Oncol. 2008; 26: 66-75
        • Hall K.H.
        • Rapini R.P.
        Acral Lentiginous Melanoma.
        in: StatPearls. StatPearls Publishing, 2022 (Available at:) (Accessed February 26, 2022)
        • Wang Y.
        • Zhao Y.
        • Ma S.
        Racial differences in six major subtypes of melanoma: descriptive epidemiology.
        BMC Cancer. 2016; 16: 691
        • Basurto-Lozada P.
        • Molina-Aguilar C.
        • Castaneda-Garcia C.
        • et al.
        Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.
        Pigment Cell Melanoma Res. 2021; 34: 59-71
        • Bradford P.T.
        • Goldstein A.M.
        • McMaster M.L.
        • et al.
        Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005.
        Arch Dermatol. 2009; 145
        • Suzuki T.
        • Ueda M.
        • Ogata K.
        • et al.
        Doses of solar ultraviolet radiation correlate with skin cancer rates in Japan.
        Kobe J Med Sci. 1996; 42: 375-388
        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
        CA: A Cancer J Clinicians. 2021; 71: 209-249
        • Bulliard J.L.
        • Cox B.
        • Elwood J.M.
        Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand.
        Cancer Causes Control. 1994; 5: 234-240
        • Duncan E.W.
        • Cramb S.M.
        • Aitken J.F.
        • et al.
        Development of the Australian Cancer Atlas: spatial modelling, visualisation, and reporting of estimates.
        Int J Health Geogr. 2019; 18: 21
      2. Melanoma Incidence and Mortality, United States–2012–2016 | CDC.
        (Available at:) (Accessed November 30, 2020)
        • Nikolaou V.
        • Stratigos A.J.
        Emerging trends in the epidemiology of melanoma.
        Br J Dermatol. 2014; 170: 11-19
        • Urban K.
        • Mehrmal S.
        • Uppal P.
        • et al.
        The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990-2017.
        JAAD Int. 2021; 2: 98-108
        • Purdue M.P.
        • Freeman L.B.
        • Anderson W.F.
        • et al.
        Recent trends in incidence of cutaneous melanoma among U.S. Caucasian young adults.
        J Invest Dermatol. 2008; 128: 2905-2908
        • Zhang M.
        • Qureshi A.A.
        • Geller A.C.
        • et al.
        Use of Tanning Beds and Incidence of Skin Cancer.
        J Clin Oncol. 2012; 30: 1588-1593
        • Gamba C.S.
        • Clarke C.A.
        • Keegan T.H.M.
        • et al.
        Melanoma Survival Disadvantage in Young, Non-Hispanic White Males Compared With Females.
        JAMA Dermatol. 2013; 149: 912-920
        • Cho E.
        • Rosner B.A.
        • Colditz G.A.
        Risk factors for melanoma by body site.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 1241-1244
        • Stanienda-Sokół K.
        • Salwowska N.
        • Sławińska M.
        • et al.
        Primary Locations of Malignant Melanoma Lesions Depending on Patients’ Gender and Age.
        Asian Pac J Cancer Prev. 2017; 18: 3081-3086
        • Juhl A.L.
        • Byers T.E.
        • Robinson W.A.
        • et al.
        The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado.
        Melanoma Res. 2009; 19: 252-259
        • Kwan T.Y.
        • Belke T.W.
        • Enta T.
        Sex differences in the anatomical distribution of melanocytic nevi in Canadian Hutterite children.
        J Cutan Med Surg. 2000; 4: 58-62
        • Visconti A.
        • Ribero S.
        • Sanna M.
        • et al.
        Body site-specific genetic effects influence naevus count distribution in women.
        Pigment Cell Melanoma Res. 2020; 33: 326-333
        • Greenwald H.S.
        • Friedman E.B.
        • Osman I.
        Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.
        Melanoma Res. 2012; 22: 1-8
        • Morton D.L.
        • Wen D.R.
        • Wong J.H.
        • et al.
        Technical details of intraoperative lymphatic mapping for early stage melanoma.
        Arch Surg. 1992; 127: 392-399
        • Kelly J.W.
        • Chamberlain A.J.
        • Staples M.P.
        • et al.
        Nodular melanoma. No longer as simple as ABC.
        Aust Fam Physician. 2003; 32: 706-709
        • Shaikh W.R.
        • Xiong M.
        • Weinstock M.A.
        The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007.
        Arch Dermatol. 2012; 148: 30-36
        • Collgros H.
        • Rodriguez-Lomba E.
        • Regio Pereira A.
        • et al.
        Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre.
        J Eur Acad Dermatol Venereol. 2021; 35: 1315-1322
        • Morton D.L.
        • Essner R.
        • Kirkwood J.M.
        • et al.
        Clinical characteristics.
        6th edition. Holland-Frei Cancer Medicine, 2003 (Available at:) (Accessed January 17, 2021)
        • Wayte D.M.
        • Helwig E.B.
        Melanotic freckle of Hutchinson.
        Cancer. 1968; 21: 893-911
        • Ward W.H.
        • Lambreton F.
        • Goel N.
        • et al.
        Clinical Presentation and Staging of Melanoma.
        in: Ward W.H. Farma J.M. Cutaneous melanoma: etiology and therapy. Codon Publications, 2017 (Available at:) (Accessed January 17, 2021)
        • Pampena R.
        • Lai M.
        • Piana S.
        • et al.
        Nevus-associated melanoma: facts and controversies.
        G Ital Dermatol Venereol. 2020; 155: 65-75
        • Lin W.M.
        • Luo S.
        • Muzikansky A.
        • et al.
        Outcome of patients with de novo versus nevus-associated melanoma.
        J Am Acad Dermatol. 2015; 72: 54-58
        • Tsao H.
        • Bevona C.
        • Goggins W.
        • et al.
        The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate.
        Arch Dermatol. 2003; 139: 282-288
        • Cymerman R.M.
        • Shao Y.
        • Wang K.
        • et al.
        De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.
        J Natl Cancer Inst. 2016; 108https://doi.org/10.1093/jnci/djw121
      3. AJCC cancer staging manual. 8th ed. Springer International Publishing, New York2017
        • Scolyer R.A.
        • Rawson R.V.
        • Gershenwald J.E.
        • et al.
        Melanoma pathology reporting and staging.
        Mod Pathol. 2020; 33: 15-24
        • Gershenwald J.E.
        • Scolyer R.A.
        • Hess K.R.
        • et al.
        Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual.
        CA Cancer J Clin. 2017; 67: 472-492
        • Trinidad C.M.
        • Torres-Cabala C.A.
        • Curry J.L.
        • et al.
        Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters.
        J Clin Pathol. 2019; 72: 265-270
        • Balch C.M.
        • Wilkerson J.A.
        • Murad T.M.
        • et al.
        The prognostic significance of ulceration of cutaneous melanoma.
        Cancer. 1980; 45: 3012-3017
        • Eigentler T.K.
        • Buettner P.G.
        • Leiter U.
        • et al.
        Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry.
        JCO. 2004; 22: 4376-4383
        • Donizy P.
        • Kaczorowski M.
        • Leskiewicz M.
        • et al.
        Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: A 5-year survival analysis.
        Oncol Rep. 2014; 32: 2735-2743
        • Thompson J.F.
        • Soong S.J.
        • Balch C.M.
        • et al.
        Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.
        J Clin Oncol. 2011; 29: 2199-2205
        • Hawes D.
        • Neville A.M.
        • Cote R.J.
        Occult metastasis.
        Biomed Pharmacother. 2001; 55: 229-242
        • Niebling M.G.
        • Haydu L.E.
        • Lo S.N.
        • et al.
        The prognostic significance of microsatellites in cutaneous melanoma.
        Mod Pathol. 2020; 33: 1369-1379
        • Read R.L.
        • Haydu L.
        • Saw R.P.M.
        • et al.
        In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy.
        Ann Surg Oncol. 2015; 22: 475-481
        • Palmer S.R.
        • Erickson L.A.
        • Ichetovkin I.
        • et al.
        Circulating Serologic and Molecular Biomarkers in Malignant Melanoma.
        Mayo Clin Proc. 2011; 86: 981-990
        • Brand C.U.
        • Ellwanger U.
        • Stroebel W.
        • et al.
        Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors.
        Cancer. 1997; 79: 2345-2353
        • Barth A.
        • Wanek L.A.
        • Morton D.L.
        Prognostic factors in 1,521 melanoma patients with distant metastases.
        J Am Coll Surg. 1995; 181: 193-201
      4. Gupta S, Tsao H. Epidemiology of Melanoma. In: ; 2017. doi:10.1007/978-3-319-35153-7_31.

        • Swetter S.M.
        • Tsao H.
        • Bichakjian C.K.
        • et al.
        Guidelines of care for the management of primary cutaneous melanoma.
        J Am Acad Dermatol. 2019; 80: 208-250
        • Niknam Leilabadi S.
        • Chen A.
        • Tsai S.
        • et al.
        Update and Review on the Surgical Management of Primary Cutaneous Melanoma.
        Healthcare (Basel). 2014; 2: 234-249
        • Coit D.G.
        • Thompson J.A.
        • Albertini M.R.
        • et al.
        Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
        J Natl Compr Canc Netw. 2019; 17: 367-402
        • Pathak S.
        • Zito P.M.
        Clinical Guidelines For The Staging, Diagnosis, and Management Of Cutaneous Malignant Melanoma.
        in: StatPearls. StatPearls Publishing, 2022 (Available at:) (Accessed March 7, 2022)
        • Gannon C.J.
        • Rousseau Jr., D.L.
        • Ross M.I.
        • et al.
        Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
        Cancer. 2006; 107: 2647-2652
        • Dzwierzynski W.W.
        Complete lymph node dissection for regional nodal metastasis.
        Clin Plast Surg. 2010; 37: 113-125
        • Leiter U.
        • Stadler R.
        • Mauch C.
        • et al.
        Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2016; 17: 757-767
        • Davies H.
        • Bignell G.R.
        • Cox C.
        • et al.
        Mutations of the BRAF gene in human cancer.
        Nature. 2002; 417: 949-954
        • Cheng S.
        • Chu P.
        • Hinshaw M.
        • et al.
        Frequency of mutations associated with targeted therapy in malignant melanoma patients.
        JCO. 2011; 29: 8597
        • Alqathama A.
        BRAF in malignant melanoma progression and metastasis: potentials and challenges.
        Am J Cancer Res. 2020; 10: 1103-1114
        • Hugdahl E.
        • Kalvenes M.B.
        • Puntervoll H.E.
        • et al.
        BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
        Br J Cancer. 2016; 114: 801-808
        • Eigentler T.
        • Assi Z.
        • Hassel J.C.
        • et al.
        Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.
        Oncotarget. 2016; 7: 36130-36137
        • McArthur G.A.
        • Chapman P.B.
        • Robert C.
        • et al.
        Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
        Lancet Oncol. 2014; 15: 323-332
        • Serrone L.
        • Zeuli M.
        • Sega F.M.
        • et al.
        Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
        J Exp Clin Cancer Res. 2000; 19: 21-34
        • Chapman P.B.
        • Hauschild A.
        • Robert C.
        • et al.
        Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation.
        New Engl J Med. 2011; 364: 2507-2516
        • Poulikakos P.I.
        • Persaud Y.
        • Janakiraman M.
        • et al.
        RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
        Nature. 2011; 480: 387-390
        • Kakadia S.
        • Yarlagadda N.
        • Awad R.
        • et al.
        Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
        Onco Targets Ther. 2018; 11: 7095-7107
        • Nazarian R.
        • Shi H.
        • Wang Q.
        • et al.
        Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
        Nature. 2010; 468: 973-977
        • Gutzmer R.
        • Stroyakovskiy D.
        • Gogas H.
        • et al.
        Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2020; 395: 1835-1844
        • Dummer R.
        • Ascierto P.A.
        • Gogas H.J.
        • et al.
        Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
        Lancet Oncol. 2018; 19: 603-615
        • Robert C.
        • Karaszewska B.
        • Schachter J.
        • et al.
        Improved overall survival in melanoma with combined dabrafenib and trametinib.
        N Engl J Med. 2015; 372: 30-39
        • Wolchok J.D.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
        N Engl J Med. 2017; 377: 1345-1356
        • Larkin J.
        • Ascierto P.A.
        • Dréno B.
        • et al.
        Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.
        New Engl J Med. 2014; 371: 1867-1876
        • Kunz M.
        • Dannemann M.
        • Kelso J.
        High-throughput sequencing of the melanoma genome.
        Exp Dermatol. 2013; 22: 10-17
        • Spain L.
        • Julve M.
        • Larkin J.
        Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.
        Expert Opin Pharmacother. 2016; 17: 1031-1038
        • Ribas A.
        • Flaherty K.T.
        BRAF targeted therapy changes the treatment paradigm in melanoma.
        Nat Rev Clin Oncol. 2011; 8: 426-433
        • Hayward N.K.
        • Wilmott J.S.
        • Waddell N.
        • et al.
        Whole-genome landscapes of major melanoma subtypes.
        Nature. 2017; 545: 175-180
        • Fedorenko I.V.
        • Gibney G.T.
        • Smalley K.S.M.
        NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
        Oncogene. 2013; 32: 3009-3018
        • Eskandarpour M.
        • Hashemi J.
        • Kanter L.
        • et al.
        Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations.
        JNCI: J Natl Cancer Inst. 2003; 95: 790-798
        • Callahan M.K.
        • Postow M.A.
        • Wolchok J.D.
        Targeting T Cell Co-receptors for Cancer Therapy.
        Immunity. 2016; 44: 1069-1078
        • Leach D.R.
        • Krummel M.F.
        • Allison J.P.
        Enhancement of antitumor immunity by CTLA-4 blockade.
        Science. 1996; 271: 1734-1736
        • Alegre M.L.
        • Frauwirth K.A.
        • Thompson C.B.
        T-cell regulation by CD28 and CTLA-4.
        Nat Rev Immunol. 2001; 1: 220-228
        • Maio M.
        • Grob J.J.
        • Aamdal S.
        • et al.
        Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
        J Clin Oncol. 2015; 33: 1191-1196
        • Pardoll D.M.
        The blockade of immune checkpoints in cancer immunotherapy.
        Nat Rev Cancer. 2012; 12: 252-264
        • Tang F.
        • Zheng P.
        Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?.
        Cell Biosci. 2018; 8: 34
        • Topalian S.L.
        • Hodi F.S.
        • Brahmer J.R.
        • et al.
        Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
        N Engl J Med. 2012; 366: 2443-2454
        • Robert C.
        • Long G.V.
        • Brady B.
        • et al.
        Nivolumab in previously untreated melanoma without BRAF mutation.
        N Engl J Med. 2015; 372: 320-330
        • Frampton A.E.
        • Sivakumar S.
        A New Combination Immunotherapy in Advanced Melanoma.
        New Engl J Med. 2022; 386: 91-92
        • Czarnecka A.M.
        • Bartnik E.
        • Fiedorowicz M.
        • et al.
        Targeted Therapy in Melanoma and Mechanisms of Resistance.
        Int J Mol Sci. 2020; 21: 4576
        • Goldberg M.V.
        • Drake C.G.
        LAG-3 in Cancer Immunotherapy.
        Curr Top Microbiol Immunol. 2011; 344: 269-278
        • Ruffo E.
        • Wu R.
        • Bruno T.C.
        • et al.
        Lymphocyte-Activation Gene 3 (LAG3): the Next Immune Checkpoint Receptor.
        Semin Immunol. 2019; 42: 101305
        • Tawbi H.A.
        • Schadendorf D.
        • Lipson E.J.
        • et al.
        Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
        N Engl J Med. 2022; 386: 24-34
        • Michielin O.
        • van Akkooi A.C.J.
        • Ascierto P.A.
        • et al.
        • ESMO Guidelines Committee
        Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 1884-1901
        • Swetter S.
        • Thompson J.A.
        NCCN Clinical Practice Guidelines in Oncology, Melanoma: Cutaneous.
        NCCN.org. 2022; 2: 2022
        • Seth R.
        • Messersmith H.
        • Kaur V.
        • et al.
        Systemic Therapy for Melanoma: ASCO Guideline.
        JCO. 2020; 38: 3947-3970
        • Trotter S.C.
        • Sroa N.
        • Winkelmann R.R.
        • et al.
        A Global Review of Melanoma Follow-up Guidelines.
        J Clin Aesthet Dermatol. 2013; 6: 18-26
        • Lideikaitė A.
        • Mozūraitienė J.
        • Letautienė S.
        Analysis of prognostic factors for melanoma patients.
        Acta Med Litu. 2017; 24: 25-34
        • Long G.V.
        • Stroyakovskiy D.
        • Gogas H.
        • et al.
        Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
        Lancet. 2015; 386: 444-451
        • Sosman J.A.
        • Kim K.B.
        • Schuchter L.
        • et al.
        Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
        N Engl J Med. 2012; 366: 707-714
        • Long G.V.
        • Trefzer U.
        • Davies M.A.
        • et al.
        Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2012; 13: 1087-1095
        • Hodi F.S.
        • O’Day S.J.
        • McDermott D.F.
        • et al.
        Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
        N Engl J Med. 2010; 363: 711-723
        • Drilon A.
        • Laetsch T.W.
        • Kummar S.
        • et al.
        Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children.
        New Engl J Med. 2018; 378: 731-739
        • Doebele R.C.
        • Drilon A.
        • Paz-Ares L.
        • et al.
        Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
        Lancet Oncol. 2020; 21: 271-282
        • Dummer R.
        • Schadendorf D.
        • Ascierto P.A.
        • et al.
        Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2017; 18: 435-445
        • Tsao H.
        • Chin L.
        • Garraway L.A.
        • et al.
        Melanoma: from mutations to medicine.
        Genes Dev. 2012; 26: 1131-1155
        • Graydon C.G.
        • Mohideen S.
        • Fowke K.R.
        LAG3’s Enigmatic Mechanism of Action.
        Front Immunol. 2020; 11: 615317